Aller au contenu principal
Accès ouvert déclaré 2025 article

Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients

0Citations signalées, ce qui n’est pas une note de qualité
28Institutions déclarées
3Pays d’affiliation déclarés

Rattachement africain : it, us, gb. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Financial toxicity (FT) is a growing issue for cancer patients worldwide. The PROFFIT questionnaire was developed in Italy to measure FT and identify its determinants in cancer patients within a public health system. METHODS: A prospective study was conducted with 221 cancer patients from 10 Italian centres between March 2021 and July 2022 to validate the PROFFIT questionnaire in patients undergoing active treatment. The PROFFIT and EORTC-QLQ-C30 questionnaires were administered. Statistical analyses were performed on the PROFFIT-score (items 1-7), the financial difficulties item (Q28), and the global health status/quality of life (HR-QOL) scale from the EORTC-QLQ-C30. Geographic disparities were also analysed. RESULTS: A total of 1149 questionnaires were completed (83 % paper-based, 17 % electronically). The median observation period was 5 months (IQR 4.5-5.8). Missing phenomenon increased over time but was not affected by the baseline PROFFIT-score. PROFFIT-score remained stable throughout treatment, with patients in Southern Italy reporting higher (worse) values. Significant associations (p < 0.0001) were found between PROFFIT-score and Q28 at all time-points. Moderate inverse correlations were observed between PROFFIT-score and HR-QOL. CONCLUSIONS: PROFFIT shows strong longitudinal validity for assessing FT in cancer patients. PROFFIT-score does not significantly change during treatment, but regional disparities highlight the need for targeted interventions, particularly in underserved areas. Further research will define cut-off values and explore FT dynamics across different patient populations. POLICY SUMMARY: PROFFIT validation analyses make the instrument suitable to measure FT in cancer patients within public health systems. In addition, it may represent a valuable tool to plan specific local health policies being sensible to macro-regional variability. Finally, on the long run, it might be useful to test the impact of policies implemented against FT.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients
Date Crossref
01/12/2025
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Economic and Financial Impacts of CancerMedication Adherence and ComplianceHealth Systems, Economic Evaluations, Quality of Life

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.